UK Regulator Clears CAMP4's Phase 1/2 Trial for SYNGAP1 Disorder
CAMP has more than doubled off its 52-week low of $1.65 on light trading volume (0.3× avg).
Summary
CAMP4 received MHRA authorization to include UK sites in its global Phase 1/2 trial of CMP-002 for SYNGAP1-related disorder. This follows clearances in Australia and Argentina, with EU filings still under review. The company reaffirms trial initiation in Q4 2026. For a $272M market cap biotech, expanding the trial footprint to a third major region is a meaningful regulatory milestone that de-risks the program's global execution. The news is incremental but positive, building on the July Australian clearance and recent $50.1M financing that extended cash runway to end of 2028.
At the time of this announcement, CAMP was trading at $4.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $271.7M. The 52-week trading range was $1.65 to $7.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.